Bio

Dr. Roberto Chulluncuy-Rivas is a Neurologist originally from Peru. He earned his medical degree from Universidad Peruana de Ciencias Aplicadas in Lima-Peru, and subsequently completed his Neurology residency at the University of Cincinnati.
Prior to his residency, he pursued his interest in Vascular Neurology through stroke rotations at the University of Miami and UCLA. During his residency at the University of Cincinnati, he was honored with induction into the Gold Humanism Honor Society and received the prestigious Arnold P. Gold Humanism and Excellence in Teaching Award.
Currently, Dr. Chulluncuy-Rivas is advancing his expertise in Vascular Neurology/Stroke as a Vascular Fellow at Stanford University.

Clinical Focus

  • Fellow
  • Vascular Neurology

Honors & Awards

  • Gold humanism and Excellence in Teaching Award, Gold Humanism Honor Society (2022)
  • Academic Excellence Group in Medicine, Universidad Peruana de Ciencias Aplicadas (2016)

Professional Education

  • Residency, University of Cincinnati, Department of Neurology, Neurology (2024)
  • Intership, University of Cincinnati, Department of Medicine, Internal Medicine (2021)
  • Medical Education, Universidad Peruana de Ciencias Aplicadas, Medicine (2017)

All Publications

  • Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection: The STOP-CAD Study. Stroke Yaghi, S., Shu, L., Mandel, D., Leon Guerrero, C. R., Henninger, N., Muppa, J., Affan, M., Ul Haq Lodhi, O., Heldner, M. R., Antonenko, K., Seiffge, D., Arnold, M., Salehi Omran, S., Crandall, R., Lester, E., Lopez Mena, D., Arauz, A., Nehme, A., Boulanger, M., Touze, E., Sousa, J. A., Sargento-Freitas, J., Barata, V., Castro-Chaves, P., Brito, M. T., Khan, M., Mallick, D., Rothstein, A., Khazaal, O., Kaufmann, J. E., Engelter, S. T., Traenka, C., Aguiar de Sousa, D., Soares, M., Rosa, S., Zhou, L. W., Gandhi, P., Field, T. S., Mancini, S., Metanis, I., Leker, R. R., Pan, K., Dantu, V., Baumgartner, K., Burton, T., Von Rennenberg, R., Nolte, C. H., Choi, R., MacDonald, J., Bavarsad Shahripour, R., Guo, X., Ghannam, M., Almajali, M., Samaniego, E. A., Sanchez, S., Rioux, B., Zine-Eddine, F., Poppe, A., Fonseca, A. C., Baptista, M. F., Cruz, D., Romoli, M., De Marco, G., Longoni, M., Keser, Z., Griffin, K., Kuohn, L., Frontera, J., Amar, J., Giles, J., Zedde, M., Pascarella, R., Grisendi, I., Nzwalo, H., Liebeskind, D. S., Molaie, A., Cavalier, A., Kam, W., Mac Grory, B., Al Kasab, S., Anadani, M., Kicielinski, K., Eltatawy, A., Chervak, L., Chulluncuy-Rivas, R., Aziz, Y., Bakradze, E., Tran, T. L., Rodrigo-Gisbert, M., Requena, M., Saleh Velez, F., Ortiz Gracia, J., Mudassani, V., de Havenon, A., Vishnu, V. Y., Yaddanapudi, S., Adams, L., Browngoehl, A., Ranasinghe, T., Dunston, R., Lynch, Z., Penckofer, M., Siegler, J., Mayer, S., Willey, J., Zubair, A., Cheng, Y. K., Sharma, R., Marto, J. P., Mendes Ferreira, V., Klein, P., Nguyen, T. N., Asad, S. D., Sarwat, Z., Balabhadra, A., Patel, S., Secchi, T., Martins, S., Mantovani, G., Kim, Y. D., Krishnaiah, B., Elangovan, C., Lingam, S., Quereshi, A., Fridman, S., Alvarado, A., Khasiyev, F., Linares, G., Mannino, M., Terruso, V., Vassilopoulou, S., Tentolouris, V., Martinez-Marino, M., Carrasco Wall, V., Indraswari, F., El Jamal, S., Liu, S., Alvi, M., Ali, F., Sarvath, M., Morsi, R. Z., Kass-Hout, T., Shi, F., Zhang, J., Sokhi, D., Said, J., Simpkins, A. N., Gomez, R., Sen, S., Ghani, M., Elnazeir, M., Xiao, H., Kala, N., Khan, F., Stretz, C., Mohammadzadeh, N., Goldstein, E., Furie, K. 2024; 55 (4): 908-918

    Abstract

    Small, randomized trials of patients with cervical artery dissection showed conflicting results regarding optimal stroke prevention strategies. We aimed to compare outcomes in patients with cervical artery dissection treated with antiplatelets versus anticoagulation.This is a multicenter observational retrospective international study (16 countries, 63 sites) that included patients with cervical artery dissection without major trauma. The exposure was antithrombotic treatment type (anticoagulation versus antiplatelets), and outcomes were subsequent ischemic stroke and major hemorrhage (intracranial or extracranial hemorrhage). We used adjusted Cox regression with inverse probability of treatment weighting to determine associations between anticoagulation and study outcomes within 30 and 180 days. The main analysis used an as-treated crossover approach and only included outcomes occurring with the above treatments.The study included 3636 patients (402 [11.1%] received exclusively anticoagulation and 2453 [67.5%] received exclusively antiplatelets). By day 180, there were 162 new ischemic strokes (4.4%) and 28 major hemorrhages (0.8%); 87.0% of ischemic strokes occurred by day 30. In adjusted Cox regression with inverse probability of treatment weighting, compared with antiplatelet therapy, anticoagulation was associated with a nonsignificantly lower risk of subsequent ischemic stroke by day 30 (adjusted hazard ratio [HR], 0.71 [95% CI, 0.45-1.12]; P=0.145) and by day 180 (adjusted HR, 0.80 [95% CI, 0.28-2.24]; P=0.670). Anticoagulation therapy was not associated with a higher risk of major hemorrhage by day 30 (adjusted HR, 1.39 [95% CI, 0.35-5.45]; P=0.637) but was by day 180 (adjusted HR, 5.56 [95% CI, 1.53-20.13]; P=0.009). In interaction analyses, patients with occlusive dissection had significantly lower ischemic stroke risk with anticoagulation (adjusted HR, 0.40 [95% CI, 0.18-0.88]; Pinteraction=0.009).Our study does not rule out the benefit of anticoagulation in reducing ischemic stroke risk, particularly in patients with occlusive dissection. If anticoagulation is chosen, it seems reasonable to switch to antiplatelet therapy before 180 days to lower the risk of major bleeding. Large prospective studies are needed to validate our findings.

    View details for DOI 10.1161/STROKEAHA.123.045731

    View details for PubMedID 38335240

  • Asymptomatic Intracerebral Hemorrhage Following Endovascular Stroke Therapy Is Not Benign: A Systematic Review and Meta-Analysis. Journal of the American Heart Association Harker, P., Aziz, Y. N., Vranic, J., Chulluncuy-Rivas, R., Previtera, M., Yaghi, S., DeHavenon, A. H., Tsivgoulis, G. K., Khatri, V., Mistry, A. M., Khatri, P., Mistry, E. A. 2024; 13 (4): e031749

    Abstract

    Asymptomatic intracerebral hemorrhage (aICH) occurs in approximately 35% of patients with acute ischemic stroke after endovascular thrombectomy. Unlike symptomatic ICH, studies evaluating the effect of aICH on outcomes have been inconclusive. We performed a systematic review and meta-analysis to evaluate the long-term effects of postendovascular thrombectomy aICH.The meta-analysis protocol was submitted to the International Prospective Register of Systematic Reviews a priori. PubMed, Scopus, and Web of Science were searched from inception through September 2023, yielding 312 studies. Two authors independently reviewed all abstracts. Included studies contained adult patients with ischemic stroke undergoing endovascular thrombectomy with follow-up imaging assessment of ICH reporting comparative outcomes according to aICH versus no ICH. After screening, 60 papers were fully reviewed, and 10 studies fulfilled inclusion criteria (n=5723 patients total, 1932 with aICH). Meta-analysis was performed using Cochrane RevMan v5.4. Effects were estimated by a random-effects model to estimate summary odds ratio (OR) of the effect of aICH versus no ICH on primary outcomes of 90-day modified Rankin Scale 3 to 6 and mortality. The presence of aICH was associated with a higher odds of 90-day mRS 3 to 6 (OR, 2.17 [95% CI, 1.81-2.60], P<0.0001, I2 46% Q 19.15) and mortality (OR, 1.72 [95% CI, 1.17-2.53], P:0.005, I2 79% Q 27.59) compared with no ICH. This difference was maintained following subgroup analysis according to hemorrhage classification and recanalization status.The presence of aICH is associated with worse 90-day functional outcomes and higher mortality. Further studies to evaluate the factors predicting aICH and treatments aimed at reducing its occurrence are warranted.

    View details for DOI 10.1161/JAHA.123.031749

    View details for PubMedID 38348800

    View details for PubMedCentralID PMC11010099

  • Conformational Response of 30S-bound IF3 to A-Site Binders Streptomycin and Kanamycin. Antibiotics (Basel, Switzerland) Chulluncuy, R., Espiche, C., Nakamoto, J. A., Fabbretti, A., Milón, P. 2016; 5 (4)

    Abstract

    Aminoglycoside antibiotics are widely used to treat infectious diseases. Among them, streptomycin and kanamycin (and derivatives) are of importance to battle multidrug-resistant (MDR) Mycobacterium tuberculosis. Both drugs bind the small ribosomal subunit (30S) and inhibit protein synthesis. Genetic, structural, and biochemical studies indicate that local and long-range conformational rearrangements of the 30S subunit account for this inhibition. Here, we use intramolecular FRET between the C- and N-terminus domains of the flexible IF3 to monitor real-time perturbations of their binding sites on the 30S platform. Steady and pre-steady state binding experiments show that both aminoglycosides bring IF3 domains apart, promoting an elongated state of the factor. Binding of Initiation Factor IF1 triggers closure of IF3 bound to the 30S complex, while both aminoglycosides revert the IF1-dependent conformation. Our results uncover dynamic perturbations across the 30S subunit, from the A-site to the platform, and suggest that both aminoglycosides could interfere with prokaryotic translation initiation by modulating the interaction between IF3 domains with the 30S platform.

    View details for DOI 10.3390/antibiotics5040038

    View details for PubMedID 27983590

    View details for PubMedCentralID PMC5187519